prescriber.co.uk ■ ANALYSIS N ever has a race against time been framed with such dire warnings of the consequences of failure. But the quest to discover new antibiotics or, at least, find a way of holding back anti microbial resistance (AMR) is a stark matter of life or death. Ten million deaths a year by 2050, according to the latest accounting. 1 Superbugs overpowering medication is a dilemma snaking through the corri dors of political power and racing through hospitals and GP surgeries in the UK. Common infections such as pneumonia will kill again, warns Dr Margaret Chan, director general of WHO, adding: "On current trends, a common disease like gonorrhoea may become untreatable. Doctors facing patients will have to say: 'I'm sorry -there's nothing I can do for you'."
The United Nations elevated AMR to crisis level at a meeting at its New York headquarters, on 21 September 2016, signalling unprecedented cooperation from heads of state, who signed up to tackle the root causes of AMR. 2 The global faultlines of antimicrobial resistance -unregulated use, prescrip tion profligacy and foodchain contami nation among others -have led to a procession of doomladen predictions with AMR even being ranked alongside terrorism as a threat to mankind. But, despite the bleak outpourings, there is cautious hope for the next generation of antibiotics.
Laboratories are humming late into the night exploring new discoveries, ingenious modes of action and the repur posing of existing drugs to roll back the antimicrobial resistance frontier. The novel use of some existing drugs, includ ing those available overthecounter, to energise antibiotics is showing promise with a topical nail fungal cream, a diar rhoea treatment and the active ingredient of the spice turmeric all contenders for a new class of antimicrobial resistance breakers designed to prolong current antibiotic use while new therapies are being pursued.
Governments are also discussing how to recalibrate reimbursement systems to encourage more industry research and development and global awareness campaigns have been launched, such as WHO World Antibiotic Awareness week, to shake all sections of society from inertia.
Antimicrobial resistance and the race to find new antibiotics
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The race is on for researchers to develop new classes of antibiotic to tackle the global crisis of increasing antimicrobial resistance (AMR Teixobactin kills Grampositive bac teria but is not active against gramneg ative bacteria, such as Escherichia coli, which are particularly complex foes. But PhD student Shu Lam has discovered a novel way of targeting Gramnegative bacteria using starshaped polymers, officially titled structurally nanoengi neered antimicrobial peptide polymers (SNAPPs). 4 Applying the engineered pep tide polymers to the bacterium causes its protective cell wall to destabilise and puts stress on the inner cell, which has, until now, been hard to reach for existing drugs. The extra good news is that these polymers are easy to produce in large numbers.
Shu, a 25yearold member of a research team based at the University of Melbourne's polymer science unit, says: "We came upon these peptide mol ecules that are produced by our bodies as part of the natural immune system to defend against bacterial infections and we thought we could possibly mimic this system by making peptides in a polymer form easily in the lab. We looked at how these peptides target bacteria and found that we could optimise from there."
The benefit of the polymers, adds Shu, is that they attack and kill bacteria with a variety of methods, making it much harder for resistance to develop. "They kill in multiple ways, the most prominent being that they bind to the cell wall and break it apart, and this is even before they enter the cells," she explains. "They don't need to enter to have a killing activ ity and that makes it very difficult for the bacteria to resist.
"My polymer disrupts and breaks the outer membrane and can have a harmful effect on the bacteria without even get ting into the inner layer, which is different to any antimicrobials being developed." The testing and refining work is expected to continue for next five years before clin ical trials start. prescriber.co.uk
Another promising lead has recently been discovered within the human nose. Scientists at the University of Tübingen, Germany found that the bacterium Staphylococcus lugdunensis was effec tive at preventing Staph. aureus from growing. They discovered that the bacte rium produced an antibiotic compound, which they named lugdunin, which is even effective against antibioticresistant strains of Staph. aureus such as MRSA. The researchers believe that the human microbiome may be the source of many more similar antibiotics.
What are pharmaceutical companies doing?
A full stream of research funding is cru cial to the fight but the Association of the British Pharmaceutical Industry (ABPI) is keen to highlight that 34 antibiotics and infectionpreventing vaccines are in the pipeline. Although many companies have departed from the field, others remain committed, with GSK a founding partner of the Innovative Medicines Initiative "New Drugs for Bad Bugs" programme, which now has a €700 million war chest and has grown to a community of 11 pharma ceutical companies and more than 100 academic and public groups sharing infor mation and boosting research.
"The spread of resistance to antibiot ics is one of the biggest threats to public health our world is facing, reducing the options available for doctors to manage lifethreatening bacterial infections," says Dr Stephen McDonough, vice president medical director UK for GSK, which has spent more than $1 billion on antibiotic research and development over the last 10 to 12 years.
"Discovering new antibiotics is extremely difficult science, and running antibiotic clinical trials in hospitals is challenging. Another hurdle is making this research economically attractive to companies. Researching new antibiotics can be very expensive and we know their use will need to be limited and very tar geted to avoid increasing resistance.
"We also need to incentivise appro priate use of antibiotics. I know aware ness of the situation has improved since I was a GP around 15 years ago but there's more we can do. GSK is provid ing scientific advice and funding aimed at encouraging the development of fast, accurate and costeffective diagnostics that will direct the use of our antibiotics only in patients that need them."
The promise is echoed by the ABPI which, naturally, wants to see reimburse ment delinked from sales because any new prescription policies will restrict antibiotics to preserve their potency and therefore result in low sales volume despite years of investment. Discussions with the Department of Health are at pace and governments around the world are collaborating to finesse a fund ing solution. The ABPI believes a pilot scheme could start in the UK next year.
"New science is very exciting but we need to make sure we can translate this into new therapies and that is often done very well by pharma companies," explains Dr Rebecca Lumsden, the ABPI's head of science policy. "A settled business model is essential to encourage companies to keep working in this space to pull this science through to a medicine. We see industry as being a partner in a solution that involves new medicines along with collaborations between governments, scientists and health systems. But patients and the general public need to understand the idea of appropriate use of antibiotics: that is a big education job and GPs need to be involved in that."
A multifaceted problem
This is no easy battle and Dr David Brown, chair of the charity Antibiotic Research UK's scientific and technical advisory committee, warns that the pipe line is slightly flattering in that the major ity of candidates are derivatives of old drugs that may only extend an antibiotic's efficacy by a few years. "Of those 34 [in the pipeline], we may only get two to four that are effective but even if they make it, resistance will still rise by the same rate as the last 10 years, so the best we can do is stand still," he warns.
Antibiotic Research UK (ANTRUK) fig ures show that sepsis causes 44,000 deaths in the UK every year, compared Prescriber January 2017 ❚ 15 prescriber.co.uk New antibiotics l ANALYSIS ■ with 35,000 from lung cancer and 16,000 from bowel cancer. Antibiotic Research UK states: "The failure to develop new antibiotics is of great con cern. Antibiotic resistance is life threat ening, with the young and old being most at risk of resistant infections. This is because these two groups have lower immunity, making them more susceptible to infection." 5 Dr Brown adds: "Doctors and phar macists have a serious problem as the whole antibiotic and bacterial infection area is incredibly complicated. The first thing they have to do is get educatedthat is not a criticism of them, it is just that things are changing. In the past, they had the luxury of a large choice of anti biotics and low infection rates but that has been reversed with high resistance and more serious infections."
He worked on the Bill Gates project to reduce the horrendous child death toll from diarrhoeal disease, which peaked at two million a year, and the multifaceted problem of tackling different viruses and bacteria has brought home the immense challenge facing the world. Doctors have to deal with dozens of bacteria with vary ing symptomology and multiple possible antibiotic treatment plans, he explains, adding: "It needs an enormous amount of expertise and it is really impossible for GPs to have that expertise, no matter how educated they are."
A new role for old drugs?
Dr Brown believes that a new commer cial model is imperative to encourage research and development, and a rapid diagnostic test that could be employed at GP surgeries needs to be developed so doctors can determine if a patient has a viral or bacterial infection to help prescription levels. But his Perspectives paper in Nature Reviews Drug Discovery shows that a range of drugs can syner gise with existing antibiotics and make them more effective against multidrug resistant bacteria. 6 It is termed a 'salvage' operation; injecting added efficacy into an exist ing class while new discoveries, which "could take decades", are developed. The paper states: "As an interim solu tion, antibiotic resistance could be 'bro ken' by coadministering appropriate nonantibiotic drugs with failing antibiot ics. Several marketed drugs that do not currently have antibacterial indications can either directly kill bacteria, reduce the antibiotic minimum inhibitory con centration when used in combination with existing antibiotics and/or mod ulate host defence through effects on host innate immunity, in particular by altering inflammation and autophagy."
These drugs include ciclopirox, a top ical treatment for fungal nail infections, which has antibacterial qualities against both Grampositive and Gramnegative bacteria, and loperamide, an opioidre ceptor agonist normally used to treat diarrhoea, which synergises with several classes of antibiotics and increases the efficacy of eight tetracycline antibiotics. Berberine, an alkaloid compound found in several plants, has proved effective against multidrugresistant bacteria such as E. coli 7 and curcumin, found in the common cooking spice turmeric, has been tested for its ability to tackle C. difficile colitis. 8 
New classes of antibiotic are crucial
Dr Brown's report highlights that: "A few new antibiotics against Grampositive have become available in recent years [see Figure 1 ] but no totally new class of antibiotic has been introduced for the treatment of Gramnegative infections for more than 40 years." Dr Brown adds: "We have failed for 40 years to come up with any new chem ical templates, which is why we have to focus on saving our current antibiotics while we work on new treatments over the next 10 to 15 years. In the meantime, we have to salvage existing treatments with antibiotic resistance breakers."
A fiveyear £14 million project to develop a rapid test for clinicians to quickly tell if a patient has a viral or bac terial infection will provide another potent weapon in the AMR arsenal. "Lack of an accurate, reliable and rapid test to distin guish bacterial infections from the vastly more common viral infections is a major factor leading to widespread prescription of antibiotics in both hospitals and in the community," says Mike Levin, professor of international child health at Imperial College London, who leads the EUfunded project involving groups in Liverpool, Newcastle and Oxford.
It is clear that outstripping AMR will require unheralded levels of political cooperation, scientific ingenuity, novel thinking and practical application across the clinical spectrum.
